IL17A and cancer: Further contributing to interruption of the dormant-associated immune tumor microenvironment is that these mRNA pro-vaccines can trigger a strong inflammatory response with elevated levels of circulating IL-17 [208] and, particularly in cancer patients previously infected with SARS-CoV2, a shift of memory T-cell toward pro-inflammatory IL-17+ CD8 [84].